What is HC Wainwright’s Forecast for ACXP FY2026 Earnings?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) – HC Wainwright cut their FY2026 earnings per share estimates for Acurx Pharmaceuticals in a report issued on Thursday, November 12th. HC Wainwright analyst M. Keller now expects that the company will post earnings of ($2.03) per share for the year, down from their prior forecast of ($2.00). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2026 earnings at ($0.46) EPS and FY2027 earnings at ($1.66) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

View Our Latest Report on ACXP

Acurx Pharmaceuticals Stock Performance

Shares of Acurx Pharmaceuticals stock opened at $0.99 on Monday. The firm has a market cap of $6.00 million, a PE ratio of -0.51 and a beta of -2.08. The business’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $1.88. Acurx Pharmaceuticals has a 52-week low of $0.90 and a 52-week high of $7.54.

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11).

Acurx Pharmaceuticals Company Profile

(Get Free Report)

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing antibiotics to treat bacterial infections, particularly those caused by Gram-positive bacteria. The company’s research centers on DNA polymerase IIIC inhibitors, a class designed to interfere with bacterial DNA replication. Its lead investigational candidate, ibezapolstat, is being developed to treat infections caused by Clostridioides difficile (C. difficile). Acurx has also pursued other antibiotic candidates for Gram-positive bacterial infections.

Read More

Earnings History and Estimates for Acurx Pharmaceuticals (NASDAQ:ACXP)

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.